logo

Search

Login | Create Account

oncology


Categories

Blood Breast cancer Cancer care Childhood cancers End-of-life care Endocrine GI cancer GU cancer Head and neck cancer Lung cancer Medicines Medicopolitical Melanoma Podcasts Radiation oncology Research Risk Factors Sarcoma

Other

Conferences

Specialties


Cardiology Dermatology Endocrinology Gastroenterology Haematology Neurology Oncology Respiratory Rheumatology

General


Contact Us About Us Website Disclaimer Privacy Policy Terms & Conditions

©2022 the limbic

logo

ASCO 2018

Saturday 1st - Saturday 5th May 2018

GU cancer

Will the CARMENA trial change your practice?

A phase 3 trial of sunitinib alone versus nephrectomy followed by sunitinib in patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC) suggests surgery may not always be necessary. The CARMENA trial presented at the ASCO 2018 meeting and published...

A phase 3 trial of sunitinib alone versus nephrectomy followed by sunitinib in patients with intermediate- and poor-risk metastatic renal...


Medicines

Cemiplimab effective in advanced SCC

A new standard of care is on the horizon for advanced cutaneous squamous cell carcinoma (SCC), a leading Australian medical oncologist has told the ASCO meeting in Chicago. Professor Danny Rischin, Director of the Division of Cancer Medicine and Head of...

A new standard of care is on the horizon for advanced cutaneous squamous cell carcinoma (SCC), a leading Australian medical...


Breast cancer

Recurrence score guides chemo use

Up to 85% of women with early ER-positive, HER2-negative, node-negative breast cancer can be spared chemotherapy, according to results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The TAILORx trial of more than 10,000 women found endocrine...

Up to 85% of women with early ER-positive, HER2-negative, node-negative breast cancer can be spared chemotherapy, according to results presented...


Cancel
Cancel